← Eichor
Condition: Cart Cells Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Cart Cells

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Quality Of Life and Drug Use in Patients With CAR-T Cells
Phase N/A · 1 location(s) · Hospices Civils de Lyon · NCT04914091Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Phase 1 · 1 location(s) · Stephan Grupp MD PhD · NCT06934382Study of AZD0754 in Participants With Metastatic Prostate Cancer
Phase 1/Phase 2 · 15 location(s) · AstraZeneca · NCT06267729A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T
Phase 1/Phase 2 · 13 location(s) · Cabaletta Bio · NCT04422912CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT07538635Phase I Study of OriC902 in Treatment of Advanced HCC
Phase 1 · 2 location(s) · Peking University · NCT06891742CAR-T Immunotherapy Targeting CD19- ALL
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT04016129A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms
Phase 1 · 35 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT06220201Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06236139Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With R
NA · 1 location(s) · Beijing Boren Hospital · NCT06983951Multi-4SCAR-T Therapy Targeting Breast Cancer
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT04430595Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic
Phase 1/Phase 2 · 2 location(s) · Gyala Therapeutics · NCT07471789A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT03050190Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
Phase 1/Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07169500Combination Immunotherapy Targeting Melanoma
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT06739226Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07106723Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Phase 1 · 1 location(s) · Polina Stepensky · NCT07085676GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL
Phase 1 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06875063The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia
EARLY_Phase 1 · 2 location(s) · Anhui Provincial Hospital · NCT06307600Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT03356782Genetically Modified T Cells Against Ovarian Cancer
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT03184753CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Stephan Grupp MD PhD · NCT07464951A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Mana
NA · 8 location(s) · National Cancer Institute (NCI) · NCT05621291Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06695013A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1 · 19 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT061532514SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT04637503Phase I Clinical Trial of CART Cell Therapy for Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescent
Phase 1 · 1 location(s) · Instituto de Investigación Hospital Universitario La Paz · NCT06709469CAR-T Immunomonitoring in Multiple Myeloma (CART I5M)
NA · 1 location(s) · Poitiers University Hospital · NCT07342179Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapi
NA · 2 location(s) · Peter MacCallum Cancer Centre, Australia · NCT07051525Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
Phase 2 · 1 location(s) · Polina Stepensky · NCT06971380
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.